

PD Dr. Stephan Götze (praxis westend Berlin)

Veröffentlichungen (Peer Reviewed Articles)

1. Ambulatory respiratory rate trends predict heart failure decompensation and hospitalization in Implantable Cardioverter Defibrillator and Biventricular Device recipients: a novel ambulatory parameter to optimize heart failure management (NOTICE-HF) S Goetze, Y Zhang, Qi An, Viktoria Averina, Pier Lambiase, Richard Schilling, Hans-Joachim Trappe, Siegmund Winter, Nicholas Wold, Ljubomir Manola, Kestens D. J Interv Card Electrophysiol. 2015 Jun;43(1):21-9
2. Three dimensional rotational venography of the coronary sinus tree facilitates left ventricular lead implantation for CRT, Jan Kaufmann , Ji Hong Gerds-Li, Charalampos Kriatselis, Eckart Fleck and S Goetze J Interv Card Electrophysiol. 2015 Mar;42(2):125-8
3. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). Healey JS, Hohnloser SH, Glikson M, Neuzner J, Mabo P, Vinolas X, Kautzner J, O'Hara G, VanErven L, Gadler F, Pogue J, Appl U, Gilkerson J, Pochet T, Stein KM, Merkely B, Chrolavicius S, Meeks B, Foldesi C, Thibault B, Connolly SJ; Shockless IMPLant Evaluation [SIMPLE] investigators.(among many S. Goetze) Lancet. 2015 Feb 28;385(9970)
4. Managed ventricular pacing compared with conventional dual-chamber pacing for elective replacement in chronically paced patients: results of the Prefer for Elective Replacement Managed Ventricular Pacing randomized study. Botto GL, Ricci RP, Bénézet JM, Nielsen JC, De Roy L, Piot O, Quesada A, Quaglione R, Vaccari D, Garutti C, Vainer L, Kozák M; Mond H, Kertes P, Strohmer B, Ebinger R, Vandekerckhove Y, Friart A, Evrard P, DeRoy L, Pantano A, Basta M, Sturmer M, Paredes F, Crystal E, Kozak M, Nielsen JC, Hojberg S, Nielsen T, Friis E, Simonsen E, Mollerus M, Jensen G, Engby B, Christensen PD, Hartikainen J, Koistinen J, Galley D, Bru P, Olivier, Camous JP, Durand P, Piot O, Götze S, Schade S, Spencker S, Will J, Yang A, Kaltofen G, Meisel E, Kloppe A, Hoppert T, Hobrack S, Apostolopoulos T, Chan R, Édes I, Katz A, Militianu A, Rosenheck S, Strassberg B, Swissa M, Luria D, Glick A, Lisi F, Botto G, Mariconti B, Delise P, Mantovani G, Padeletti L, Magliari F, Vaccari D, Fedele F, Quaglione R, Santini M, Puntrello C, Al Kandari F, van Gelder I, Conceicao J, de Sousa J, Kaliská G, Kim JS, Mont JL, Diago Torrent JL, Bénézet JM, Quesada A, Sancho Tello MJ, Sotillo Marti JF, Herreros B, Osswald S., Heart Rhythm. 2014 Jun;11(6):992-1000

5. Electromagnetic Interference of Avalanche Transceivers with Cardiac Pacemakers and Implantable Cardioverter Defibrillators. Dorenkamp M, Blaschke F, Voigt K, Fleck E, Goetze S, Roser M. *Pacing Clin Electrophysiol.* 2013 May 36(8):931-8
6. Phrenic nerve stimulation in CRT patients and benefits of electronic lead repositioning: The ERACE trial
Stephan Goetze. Pascal Defaye, Alexander Bauer, Matthias Merkel, Olivier Bizeau, Sven Treusch, Klaus Contzen, Claus Juenger, Joachim Winter, *JICE*; 2013(DOI 10.1007/s10840-013-9811-9
7. Combined use of three-dimensional rotational angiogram of left atrium and circular multi-electrode ablation catheter for pulmonary vein isolation. Tang M, Kriatselis C, Nedics S, Roser M, Goetze S, Fleck E, Gerds-Li JH. *Chin Med J (Engl).* 2012 Jan;125(1):144-8
8. Remote monitoring of heart failure patients using implantable cardiac pacing devices and external sensors: results of the Insight-HF study. Lieback A, Proff J, Wessel K, Fleck E, Götze S. *Clin Res Cardiol.* 2011 Oct 5.
9. Chronic CRP-exposure inhibits VEGF-induced endothelial cell migration. Schneeweis C, Gräfe M, Bungenstock A, Spencer-Hänsch C, Fleck E, Goetze S. *J Atheroscler Thromb.* 2010 Feb 26;17(2):203-12. Epub 2010 Feb 22
10. Magnetic resonance imaging for monitoring the efficacy of thrombolytic therapy in subacute pulmonary artery embolism. Jahnke C, Kaufmann J, Stauber B, Goetze S, Fleck E, Paetsch I. *J Am Coll Cardiol.* 2009 Sep 29;54(14):1335.
11. Rapid ventricular pacing to optimize rotational angiography in atrial fibrillation ablation. Gerds-Li JH, Tang M, Kriatselis C, Roser M, Goetze S, He D, Fleck E. *J Interv Card Electrophysiol.* 2009 Nov;26(2):101-7. Epub 2009 Apr 22
12. ICD-Therapie - Wie viel ist evidenzbasiert? M. Roser · S. Götze
Der Kardiologe 2007, DOI 10.1007/s12181-007-0019-z

13. Performance Evaluation of a Right Atrial Automatic Capture Verification Algorithm using Two Different Sensing Configurations. Sperzel J, Goetze S, Kennergren C, Biffi M, Brooke MJ, Vireca E, Saha S, Schubert B, Butter B. *Pacing Clin Electrophysiol.* 2009 2009 May;32(5):579-87.
14. Visualization of the cardiac venous system using cardiac magnetic resonance. Chibiri A, Kelle S, Goetze S, Kriatselis C, Thouet T, Tangcharoen T, Paetsch I, Schnackeburg B, Fleck E, Nagel E. *Am J Cardiol.* 2008 Feb 1;101(3):407-12
15. Managed ventricular pacing vs. conventional dual-chamber pacing for elective replacements: the PreFER MVP study: clinical background, rationale, and design. Quesada A, Botto G, Erdogan A, Kozak M, Lercher P, Nielsen JC, Piot O, Ricci R, Weiss C, Becker D, Wetzels G, De Roy L; Quaglione R, Vaccari D, Garutti C, Vainer L, Mond H, Kertes P, Strohmer B, Ebinger R, Vandekerckhove Y, Friart A, Evrard P, DeRoy L, Pantano A, Basta M, Sturmer M, Paredes F, Crystal E, Nielsen T, Friis E, Simonsen E, Mollerus M, Jensen G, Engby B, Christensen PD, Hartikainen J, Koistinen J, Galley D, Bru P, Olivier, Camous JP, Durand P, Piot O, Götze S, Schade S, Spencker S, Will J, Yang A, Kaltofen G, Meisel E, Kloppe A, Hoppert T, Hobrack S, Apostolopoulos T, Chan R, Édes I, Katz A, Militianu A, Rosenheck S, Strassberg B, Swissa M, Luria D, Glick A, Lisi F, Botto G, Mariconti B, Delise P, Mantovani G, Padeletti L, Magliari F, Vaccari D, Fedele F, Quaglione R, Santini M, Puntrello C, Al Kandari F, van Gelder I, Conceicao J, de Sousa J, Kaliská G, Kim JS, Mont JL, Diago Torrent JL, Bénézet JM, Quesada A, Sancho Tello MJ, Sotillo Marti JF, Herreros B, *Europace.* 2008 Mar;10(3):321-6
16. Clinical evaluation of two different evoked response sensing methods for automatic capture detection in the left ventricle. Goetze S, Sperzel J, Biffi M; Sathaye A, Brooke MJ, Doelger A, Schubert B, Butter C. *Pacing Clin Electrophysiol.* 2007 Jul;30 (7):865-73.
17. Cardiac resynchronization therapy for heart failure - from experimental pacing to evidence-based therapy. Goetze S, Butter C, Fleck E. *Clin Res in Cardiology* 2006; 95 (Suppl 4): 18-33
18. Endoproteolytic activation of alpha(v) integrin by proprotein convertase PC5 is required for vascular smooth muscle cell adhesion to vitronectin and integrin-dependent signaling. Stawowy P, Kallisch H, Veinot JP, Kilimnik A, Prichett W, Goetze S, Seidah NG, Chrétien M, Fleck E, Graf K. *Circulation.* 2004 Feb 17;109(6):770-6.

19. Coordinated regulation and colocalization of alpha_v integrin and its activating enzyme proprotein convertase PC5 in vivo. Stawowy P, Kallisch H, Veinot JP, Kilimnik A, Prichett W, Goetze S, Seidah NG, Chrétien M, Fleck E, Graf K. *Histochem Cell Biol.* 2003 Mar;119(3):239-45. Epub 2003 Feb 20
20. LPS regulate ERK1/2-dependent signaling in cardiac fibroblasts via PKC-mediated MKP-1 induction. Stawowy P, Kallisch H, Veinot JP, Kilimnik A, Prichett W, Goetze S, Seidah NG, Chrétien M, Fleck E, Graf K. *Biochem Biophys Res Commun.* 2003 Mar 28;303(1):74-80.
21. Statins regulate alpha₂beta₁-integrin expression and collagen I-dependent functions in human vascular smooth muscle cells. Graf K, Kappert K, Stawowy P, Bokemeyer J, Blaschke F, Schmidt G, Kintscher U, Goetze S, Fleck E. *J Cardiovasc Pharmacol.* 2003 Jan;41(1):89-96.
22. PPARalpha inhibits TGF-beta-induced beta₅ integrin transcription in vascular smooth muscle cells by interacting with Smad4. Kintscher U, Lyon C, Wakino S, Bruemmer D, Feng X, Goetze S, Graf K, Moustakas A, Staels B, Fleck E, Hsueh WA, Law RE. *Circ Res.* 2002 Nov 29;91(11):e35-44.
23. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, Spencer-Hänsch C, Graf K, Nürnberg B, Law RE, Fleck E, Gräfe M. *Hypertension.* 2002 Nov;40(5):748-54.
24. TGF-beta(1) induces peroxisome proliferator-activated receptor gamma₁ and gamma₂ expression in human THP-1 monocytes. Kintscher U, Wakino S, Bruemmer D, Goetze S, Graf K, Hsueh WA, Law RE. *Biochem Biophys Res Commun.* 2002 Oct 4;297(4):794-9.
25. Hypoxia activates beta(1)-integrin via ERK 1/2 and p38 MAP kinase in human vascular smooth muscle cells. Blaschke F, Stawowy P, Goetze S, Hintz O, Gräfe M, Kintscher U, Fleck E, Graf K. *Biochem Biophys Res Commun.* 2002 Aug 30;296(4):890-6.
26. Angiotensin II-augmented migration of VSMCs towards PDGF-BB involves Pyk2 and ERK 1/2 activation. Blaschke F, Stawowy P, Kappert K, Goetze S, Kintscher U, Wollert-Wulf B, Fleck E, Graf K. *Basic Res Cardiol.* 2002 Jul;97(4):334-42.
27. PPAR activators inhibit endothelial cell migration by targeting Akt. Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, Blaschke F, Graf K, Law RE, Fleck E, Gräfe M. *Biochem Biophys Res Commun.* 2002 May 24;293(5):1431-7.

28. Increased myocardial expression of osteopontin in patients with advanced heart failure. Stawowy P, Blaschke F, Pfautsch P, Goetze S, Lippek F, Wollert-Wulf B, Fleck E, Graf K. Eur J Heart Fail. 2002 Mar;4(2):139-46.
29. Proprotein convertase PC5 regulation by PDGF-BB involves PI3-kinase/p70(s6)-kinase activation in vascular smooth muscle cells. Stawowy P, Blaschke F, Kilimnik A, Goetze S, Kallisch H, Chrétien M, Marcinkiewicz M, Fleck E, Graf K Hypertension. 2002 Feb;39(2 Pt 2):399-404.

30. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration. Goetze S, Kintscher U, Kim S, Meehan WP, Kaneshiro K, Collins AR, Fleck E, Hsueh WA, Law RE. *J Cardiovasc Pharmacol.* 2001 Dec;38(6):909-21.
31. TNFalpha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2. Goetze S, Kintscher U, Kaneshiro K, Meehan WP, Collins A, Fleck E, Hsueh WA, Law RE. *Atherosclerosis.* 2001 Nov;159(1):93-101.
32. TNFalpha inhibits insulin's antiapoptotic signaling in vascular smooth muscle cells. Goetze S, Blaschke F, Stawowy P, Bruemmer D, Spencer C, Graf K, Gräfe M, Law RE, Fleck E. *Biochem Biophys Res Commun.* 2001 Sep 28;287(3):662-70.
33. Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes. Kintscher U, Kon D, Wakino S, Goetze S, Graf K, Fleck E, Hsueh WA, Law RE. *J Cardiovasc Pharmacol.* 2001 May;37(5):532-9.
34. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, Law RE. *Eur J Pharmacol.* 2000 Aug 11;401(3):259-70.
35. Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells. Goetze S, Kim S, Xi XP, Graf K, Yang DC, Fleck E, Meehan WP, Hsueh WA, Law RE. *J Cardiovasc Pharmacol.* 2000 May;35(5):749-57.
36. Tumor necrosis factor alpha inhibits insulin-induced mitogenic signaling in vascular smooth muscle cells. Goetze S, Kintscher U, Kawano H, Kawano Y, Wakino S, Fleck E, Hsueh WA, Law RE. *J Biol Chem.* 2000 Jun 16;275(24):18279-83.
37. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. *Circulation.* 2000 Mar 21;101(11):1311-8.

38. Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts. Kawano H, Cody RJ, Graf K, Goetze S, Kawano Y, Schnee J, Law RE, Hsueh WA. Hypertension. 2000 Jan;35(1 Pt 2):273-9.
39. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. Goetze S, Xi XP, Graf K, Fleck E, Hsueh WA, Law RE. FEBS Lett. 1999 Jun 11;452(3):277-82.
40. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, Law RE. J Cardiovasc Pharmacol. 1999 May;33(5):798-806.
41. TNF-alpha-induced migration of vascular smooth muscle cells is MAPK dependent. Goetze S, Xi XP, Kawano Y, Kawano H, Fleck E, Hsueh WA, Law RE. Hypertension. 1999 Jan;33(1 Pt 2):183-9.
42. Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Xi XP, Graf K, Goetze S, Fleck E, Hsueh WA, Law RE. Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):73-82.
43. Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells. Xi XP, Graf K, Goetze S, Hsueh WA, Law RE. FEBS Lett. 1997 Nov 17;417(3):283-6.
44. Changes of fluid-dynamic parameters in peripheral stenoses with transcatheter interventions. Wellnhofer E, Biamino G, Sauer HU, Trebeljahr A, Stalke J, Ragg C, Oswald H, Gotze S, Fleck E, Felix R. Eur Heart J. 1995 Oct;16 Suppl J:60-70.
45. Regulation of vascular tone during treatment with cyclosporine A: modulation of endothelial and vascular smooth muscle function. Götze S, Auch-Schwelk W, Duske E, Fleck E. Endothelium 1996; 4, 159-169.
46. Selective downregulation of rat cardiac beta 1-adrenoceptors by cyclosporine A: prevention by diltiazem or angiotensin-converting enzyme inhibitors. Brodde OE, Adamczyk M, Busch F, Bossaller C, Duske E, Fleck E, Götze S, Auch-Schwelk W. J Am Coll Cardiol. 1995 Mar 1;25(3):761-7

47. Preventive effects of diltiazem on cyclosporin A-induced vascular smooth muscle dysfunction. Götze S, Auch-Schwelk W, Bossaller C, Thelen J, Fleck E. *Transpl Int.* 1994 May;7(3):157-62.
48. Calcium entry blockade may prevent cyclosporin A-induced hypersensitivity to angiotensin II and endothelial dysfunction in the rat aorta. Götze S, Auch-Schwelk W, Bossaller C, Thelen J, Fleck E. *Eur Heart J.* 1993 Nov;14 Suppl I:104-10.
49. Endothelial and vascular smooth muscle function after chronic treatment with cyclosporin A. Auch-Schwelk W, Bossaller C, Götze S, Thelen J, Fleck E. *J Cardiovasc Pharmacol.* 1993 Mar;21(3):435-40.
50. Endothelium-dependent relaxations are augmented in rats chronically treated with the angiotensin-converting enzyme inhibitor enalapril. Bossaller C, Auch-Schwelk W, Weber F, Götze S, Gräfe M, Graf K, Fleck E. *J Cardiovasc Pharmacol.* 1992;20 Suppl 9:S91-5